{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T11:42:56Z","timestamp":1770723776652,"version":"3.49.0"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,9,27]],"date-time":"2016-09-27T00:00:00Z","timestamp":1474934400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1007\/s40256-016-0192-1","type":"journal-article","created":{"date-parts":[[2016,9,27]],"date-time":"2016-09-27T14:51:53Z","timestamp":1474987913000},"page":"5-16","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Optimizing the Use of Cangrelor in the Real World"],"prefix":"10.1007","volume":"17","author":[{"given":"Arman","family":"Qamar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepak L.","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,9,27]]},"reference":[{"key":"192_CR1","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1146\/annurev-pharmtox-010814-124438","volume":"55","author":"JP Depta","year":"2015","unstructured":"Depta JP, Bhatt DL. New approaches to inhibiting platelets and coagulation. Annu Rev Pharmacol Toxicol. 2015;55:373\u201397.","journal-title":"Annu Rev Pharmacol Toxicol."},{"issue":"12","key":"192_CR2","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1161\/CIRCRESAHA.114.302737","volume":"114","author":"DL Bhatt","year":"2014","unstructured":"Bhatt DL, Hulot JS, Moliterno DJ, et al. Antiplatelet and anticoagulation therapy for acute coronary syndromes. Circ Res. 2014;114(12):1929\u201343.","journal-title":"Circ Res."},{"issue":"4","key":"192_CR3","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jacc.2012.11.019","volume":"61","author":"PT O\u2019Gara","year":"2013","unstructured":"O\u2019Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;61(4):78\u2013140.","journal-title":"J Am Coll Cardiol."},{"issue":"24","key":"192_CR4","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jacc.2014.09.017","volume":"64","author":"EA Amsterdam","year":"2014","unstructured":"Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;64(24):139\u2013228.","journal-title":"J Am Coll Cardiol."},{"issue":"20","key":"192_CR5","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1093\/eurheartj\/ehs215","volume":"33","author":"PG Steg","year":"2012","unstructured":"Steg PG, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology (ESC). Eur Heart J. 2012;33(20):2569\u2013619.","journal-title":"Eur Heart J."},{"issue":"3","key":"192_CR6","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","volume":"37","author":"M Roffi","year":"2016","unstructured":"Roffi M, Patrono C, Collet JP, et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the Management of Acute Coronary Syndromes (ACS) in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(3):267\u2013315.","journal-title":"Eur Heart J."},{"issue":"7","key":"192_CR7","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","volume":"345","author":"S Yusuf","year":"2001","unstructured":"Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345(7):494\u2013502.","journal-title":"N Engl J Med."},{"issue":"9281","key":"192_CR8","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","volume":"358","author":"SR Mehta","year":"2001","unstructured":"Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358(9281):527\u201333.","journal-title":"Lancet."},{"issue":"12","key":"192_CR9","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1056\/NEJMoa050522","volume":"352","author":"MS Sabatine","year":"2005","unstructured":"Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005;352(12):1179\u201389.","journal-title":"N Engl J Med."},{"issue":"8","key":"192_CR10","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1001\/jama.2009.1249","volume":"302","author":"DL Bhatt","year":"2009","unstructured":"Bhatt DL. Tailoring antiplatelet therapy based on pharmacogenomics: how well do the data fit? JAMA. 2009;302(8):896\u20137.","journal-title":"JAMA."},{"issue":"4","key":"192_CR11","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa0809171","volume":"360","author":"JL Mega","year":"2009","unstructured":"Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphism and response to clopidogrel. N Engl J Med. 2009;360(4):354\u201362.","journal-title":"N Engl J Med."},{"issue":"4","key":"192_CR12","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJMoa0808227","volume":"360","author":"T Simon","year":"2009","unstructured":"Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360(4):363\u201375.","journal-title":"N Engl J Med."},{"issue":"9660","key":"192_CR13","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(08)61845-0","volume":"373","author":"JP Collet","year":"2009","unstructured":"Collet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet. 2009;373(9660):309\u201317.","journal-title":"Lancet."},{"issue":"20","key":"192_CR14","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","volume":"357","author":"SD Wiviott","year":"2007","unstructured":"Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001\u201315.","journal-title":"N Engl J Med."},{"issue":"20","key":"192_CR15","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMe0706859","volume":"357","author":"DL Bhatt","year":"2007","unstructured":"Bhatt DL. Intensifying platelet inhibition-navigating between Scylla and Charybdis. N Engl J Med. 2007;357(20):2078\u201381.","journal-title":"N Engl J Med."},{"issue":"11","key":"192_CR16","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","volume":"361","author":"L Wallentin","year":"2009","unstructured":"Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndrome. N Engl J Med. 2009;361(11):1045\u201357.","journal-title":"N Engl J Med."},{"issue":"12","key":"192_CR17","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/nrcardio.2009.192","volume":"6","author":"DL Bhatt","year":"2009","unstructured":"Bhatt DL. Antiplatelet therapy: ticagrelor in ACS\u2013what does PLATO teach us? Nat Rev Cardiol. 2009;6(12):737\u20138.","journal-title":"Nat Rev Cardiol."},{"issue":"7","key":"192_CR18","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.jacc.2013.10.068","volume":"63","author":"EL Hobl","year":"2014","unstructured":"Hobl EL, Stimpfl T, Ebner J, et al. Morphine decreases clopidogrel concentrations and effects: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 2014;63(7):630\u20135.","journal-title":"J Am Coll Cardiol."},{"issue":"4","key":"192_CR19","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s00392-015-0927-z","volume":"105","author":"EL Hobl","year":"2016","unstructured":"Hobl EL, Reiter B, Schoergenhofer C, et al. Morphine interaction with prasugrel: a double-blind, cross-over trial in healthy volunteers. Clin Res Cardiol. 2016;105(4):349\u201355.","journal-title":"Clin Res Cardiol."},{"issue":"1","key":"192_CR20","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/eci.12550","volume":"46","author":"EL Hobl","year":"2016","unstructured":"Hobl EL, Reiter B, Schoergenhofer C, et al. Morphine decreases ticagrelor concentrations but not its antiplatelet effects: a randomized trial in healthy volunteers. Eur J Clin Invest. 2016;46(1):7\u201314.","journal-title":"Eur J Clin Invest."},{"issue":"3","key":"192_CR21","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s00228-012-1360-0","volume":"69","author":"L Souckova","year":"2013","unstructured":"Souckova L, Opatrilova R, Suk P, et al. Impaired bioavailability and antiplatelet effect of high-dose clopidogrel in patients after cardiopulmonary resuscitation. Eur J Clin Pharmacol. 2013;69(3):309\u201317.","journal-title":"Eur J Clin Pharmacol."},{"issue":"9","key":"192_CR22","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1161\/CIRCULATIONAHA.111.044107","volume":"124","author":"HM Krumholz","year":"2011","unstructured":"Krumholz HM, Herrin J, Miller LE, et al. Improvement in door-to-balloon time in the United States, 2005 to 2010. Circulation. 2011;124(9):1038\u201345.","journal-title":"Circulation."},{"issue":"6","key":"192_CR23","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1161\/CIRCINTERVENTIONS.112.972323","volume":"5","author":"D Alexopoulos","year":"2012","unstructured":"Alexopoulos D, Xanthopoulou I, Gkizas V, et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv. 2012;5(6):797\u2013804.","journal-title":"Circ Cardiovasc Interv."},{"issue":"1","key":"192_CR24","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ahj.2015.04.012","volume":"170","author":"D Alexopoulos","year":"2015","unstructured":"Alexopoulos D, Bhatt DL, Hamm CW, et al. Early P2Y12 inhibition in ST-segment elevation myocardial infarction: bridging the gap. Am Heart J. 2015;170(1):3\u201312.","journal-title":"Am Heart J."},{"issue":"3","key":"192_CR25","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nrcardio.2012.199","volume":"10","author":"K Agrawal","year":"2013","unstructured":"Agrawal K, Bhatt DL. Antiplatelet therapy: does prasugrel or ticagrelor suffice in patients with STEMI? Nat Rev Cardiol. 2013;10(3):121\u20132.","journal-title":"Nat Rev Cardiol."},{"issue":"11","key":"192_CR26","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/j.jcin.2015.02.030","volume":"8","author":"F Franchi","year":"2015","unstructured":"Franchi F, Rollini F, Cho JR, et al. Impact of escalating loading dose regimens of ticagrelor in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of a prospective randomized pharmacokinetic and pharmacodynamic investigation. JACC Cardiovasc Interv. 2015;8(11):1457\u201367.","journal-title":"JACC Cardiovasc Interv."},{"issue":"17","key":"192_CR27","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/j.jacc.2016.02.045","volume":"67","author":"F Rollini","year":"2016","unstructured":"Rollini F, Franchi F, Hu J, et al. Crushed prasugrel tablets in patients with STEMI undergoing primary percutaneous coronary intervention: the CRUSH study. J Am Coll Cardiol. 2016;67(17):1994\u20132004.","journal-title":"J Am Coll Cardiol."},{"issue":"11","key":"192_CR28","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1056\/NEJMoa1308075","volume":"369","author":"G Montalescot","year":"2013","unstructured":"Montalescot G, Bolognese L, Dudek D, et al. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med. 2013;369(11):999\u20131010.","journal-title":"N Engl J Med."},{"issue":"12","key":"192_CR29","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1093\/eurheartj\/ehn169","volume":"29","author":"P Widimsky","year":"2008","unstructured":"Widimsky P, Motovska Z, Simek S, et al. Clopidogrel pre-treatment in stable angina: for all patients >6\u00a0h before elective coronary angiography or only for angiographically selected patients a few minutes before PCI? A randomized multicentre trial PRAGUE-8. Eur Heart J. 2008;29(12):1495\u2013503.","journal-title":"Eur Heart J."},{"issue":"19","key":"192_CR30","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","volume":"288","author":"SR Steinhubl","year":"2002","unstructured":"Steinhubl SR, Berger PB, Mann JT 3rd, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288(19):2411\u201320.","journal-title":"JAMA."},{"issue":"10","key":"192_CR31","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1001\/jama.294.10.1224","volume":"294","author":"MS Sabatine","year":"2005","unstructured":"Sabatine MS, Cannon CP, Gibson CM, et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA. 2005;294(10):1224\u201332.","journal-title":"JAMA."},{"issue":"17","key":"192_CR32","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.2146\/ajhp100008","volume":"67","author":"BB Dean","year":"2010","unstructured":"Dean BB, Yu HT, Bae JP, et al. Pattern of clopidogrel use in hospitalized patients receiving percutaneous coronary interventions. Am J Health Syst Pharm. 2010;67(17):1430\u20137.","journal-title":"Am J Health Syst Pharm."},{"issue":"3","key":"192_CR33","doi-asserted-by":"crossref","first-page":"e002301","DOI":"10.1161\/CIRCINTERVENTIONS.114.002301","volume":"8","author":"D Capodanno","year":"2015","unstructured":"Capodanno D, Angiolillo DJ. Pretreatment with antiplatelet drugs in invasively managed patients with coronary artery disease in the contemporary era: review of the evidence and practice guidelines. Circ Cardiovasc Interv. 2015;8(3):e002301.","journal-title":"Circ Cardiovasc Interv."},{"issue":"9","key":"192_CR34","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.amjcard.2016.02.012","volume":"117","author":"W Fan","year":"2016","unstructured":"Fan W, Plent S, Prats J, et al. Trends in P2Y12 inhibitor use in patients referred for invasive evaluation of coronary artery disease in contemporary US practice. Am J Cardiol. 2016;117(9):1439\u201343.","journal-title":"Am J Cardiol."},{"issue":"10","key":"192_CR35","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1161\/01.CIR.0000140675.85342.1B","volume":"110","author":"KA Fox","year":"2004","unstructured":"Fox KA, Mehta SR, Peters R, et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic events (CURE) trial. Circulation. 2004;110(10):1202\u20138.","journal-title":"Circulation."},{"issue":"12","key":"192_CR36","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1001\/jama.284.12.1549","volume":"284","author":"DL Bhatt","year":"2000","unstructured":"Bhatt DL, Topol EJ. Current role of platelet glycoprotein IIb\/IIIa inhibitors in acute coronary syndromes. JAMA. 2000;284(12):1549\u201358.","journal-title":"JAMA."},{"issue":"1","key":"192_CR37","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s11239-012-0737-3","volume":"34","author":"DJ Angiolillo","year":"2012","unstructured":"Angiolillo DJ, Schneider DJ, Bhatt DL, et al. Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) trials. J Thromb Thrombolysis. 2012;34(1):44\u201355.","journal-title":"J Thromb Thrombolysis."},{"key":"192_CR38","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.pharmthera.2016.01.004","volume":"159","author":"A Qamar","year":"2016","unstructured":"Qamar A, Bhatt DL. Current status of data on cangrelor. Pharmacol Ther. 2016;159:102\u20139.","journal-title":"Pharmacol Ther."},{"issue":"1","key":"192_CR39","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/0091270009344986","volume":"50","author":"WS Akers","year":"2010","unstructured":"Akers WS, Oh JJ, Oestreich JH, et al. Pharmacokinetics and pharmacodynamics of a bolus and infusion of cangrelor: a direct, and parenteral P2Y12 receptor antagonist. J Clin Pharmacol. 2010;50(1):27\u201335.","journal-title":"J Clin Pharmacol."},{"issue":"3","key":"192_CR40","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s11239-015-1233-3","volume":"40","author":"DJ Angiolillo","year":"2015","unstructured":"Angiolillo DJ, Bhatt DL, Steg PG, et al. Impact of cangrelor overdosing on bleeding complications in patients undergoing percutaneous coronary intervention: insights from the CHAMPION trials. J Thromb Thrombolysis. 2015;40(3):317\u201322.","journal-title":"J Thromb Thrombolysis."},{"issue":"24","key":"192_CR41","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1056\/NEJMoa0908628","volume":"361","author":"RA Harrington","year":"2009","unstructured":"Harrington RA, Stone GW, McNulty S, et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med. 2009;361(24):2318\u201329.","journal-title":"N Engl J Med."},{"issue":"24","key":"192_CR42","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMoa0908629","volume":"361","author":"DL Bhatt","year":"2009","unstructured":"Bhatt DL, Lincoff AM, Gibson CM, et al. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med. 2009;361(24):2330\u201341.","journal-title":"N Engl J Med."},{"issue":"5","key":"192_CR43","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.ahj.2012.02.018","volume":"163","author":"S Leonardi","year":"2012","unstructured":"Leonardi S, Mahaffey KW, White HD, et al. Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX. Am Heart J. 2012;163(5):768\u201376.","journal-title":"Am Heart J."},{"issue":"14","key":"192_CR44","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1056\/NEJMoa1300815","volume":"368","author":"DL Bhatt","year":"2013","unstructured":"Bhatt DL, Stone GW, Mahaffey KW, et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med. 2013;368(14):1303\u201313.","journal-title":"N Engl J Med."},{"issue":"2","key":"192_CR45","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ahj.2011.11.001","volume":"163","author":"HD White","year":"2012","unstructured":"White HD, Chew DP, Dauerman HL, et al. Reduced immediate ischemic events with cangrelor in PCI: a pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction. Am Heart J. 2012;163(2):182\u201390.","journal-title":"Am Heart J."},{"issue":"9909","key":"192_CR46","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1016\/S0140-6736(13)61615-3","volume":"382","author":"PG Steg","year":"2013","unstructured":"Steg PG, Bhatt DL, Hamm CW, et al. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. Lancet. 2013;382(9909):1981\u201392.","journal-title":"Lancet."},{"issue":"1","key":"192_CR47","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jcin.2012.08.018","volume":"6","author":"SJ Brener","year":"2013","unstructured":"Brener SJ, Cristea E, Kirtane AJ, et al. Intra-procedural stent thrombosis: a new risk factor for adverse outcomes in patients undergoing percutaneous coronary intervention for acute coronary syndromes. JACC Cardiovasc Interv. 2013;6(1):36\u201343.","journal-title":"JACC Cardiovasc Interv."},{"issue":"7","key":"192_CR48","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.jacc.2013.10.022","volume":"63","author":"P G\u00e8n\u00e8reux","year":"2014","unstructured":"G\u00e8n\u00e8reux P, Stone GW, Harrington RA, et al. Impact of intraprocedural stent thrombosis during percutaneous coronary intervention: insights from the CHAMPION PHOENIX trial (clinical trial comparing cangrelor to clopidogrel standard of care therapy in subjects who require percutaneous coronary intervention). J Am Coll Cardiol. 2014;63(7):619\u201329.","journal-title":"J Am Coll Cardiol."},{"key":"192_CR49","doi-asserted-by":"crossref","unstructured":"Cavender MA, Bhatt DL, Stone GW, et al. Consistent reduction in peri-procedural myocardial infarction with cangrelor as assessed by multiple definitions: findings from CHAMPION PHOENIX. Circulation. 2016;134(9). (Epub ahead of print).","DOI":"10.1161\/CIRCULATIONAHA.115.020829"},{"issue":"6","key":"192_CR50","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1001\/jama.286.6.708","volume":"286","author":"PY Lee","year":"2001","unstructured":"Lee PY, Alexander KP, Hammill BG, et al. Representation of elderly persons and women in published randomized trials of acute coronary syndromes. JAMA. 2001;286(6):708\u201313.","journal-title":"JAMA."},{"issue":"10","key":"192_CR51","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.jacc.2011.09.075","volume":"59","author":"TY Wang","year":"2012","unstructured":"Wang TY, Angiolillo DJ, Cushman M, et al. Platelet biology and response to antiplatelet therapy in women: implications for the development and use of antiplatelet pharmacotherapies for cardiovascular disease. J Am Coll Cardiol. 2012;59(10):891\u2013900.","journal-title":"J Am Coll Cardiol."},{"issue":"21","key":"192_CR52","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1016\/j.jacc.2009.05.074","volume":"54","author":"JS Berger","year":"2009","unstructured":"Berger JS, Bhatt DL, Cannon CP, et al. The relative efficacy and safety of clopidogrel in women and men a sex-specific collaborative meta-analysis. J Am Coll Cardiol. 2009;54(21):1935\u201345.","journal-title":"J Am Coll Cardiol."},{"issue":"3","key":"192_CR53","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1001\/jama.295.3.306","volume":"295","author":"JS Berger","year":"2006","unstructured":"Berger JS, Roncaglioni MC, Avanzini F, et al. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA. 2006;295(3):306\u201313.","journal-title":"JAMA."},{"issue":"3","key":"192_CR54","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1161\/CIRCULATIONAHA.115.017300","volume":"133","author":"ML O\u2019Donoghue","year":"2016","unstructured":"O\u2019Donoghue ML, Bhatt DL, Stone GW, et al. Efficacy and safety of cangrelor in women versus men during percutaneous coronary intervention: insights from the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PHOENIX) trial. Circulation. 2016;133(3):248\u201355.","journal-title":"Circulation."},{"issue":"3","key":"192_CR55","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0735-1097(00)00777-4","volume":"36","author":"WB Batchelor","year":"2000","unstructured":"Batchelor WB, Anstrom KJ, Muhlbaier LH, et al. Contemporary outcome trends in the elderly undergoing percutaneous coronary interventions: results in 7,472 octogenarians. National Cardiovascular Network Collaboration. J Am Coll Cardiol. 2000;36(3):723\u201330.","journal-title":"J Am Coll Cardiol."},{"issue":"4","key":"192_CR56","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.ahj.2007.11.007","volume":"155","author":"PJ Vlaar","year":"2008","unstructured":"Vlaar PJ, Lennon RJ, Rihal CS, et al. Drug-eluting stents in octogenarians: early and intermediate outcome. Am Heart J. 2008;155(4):680\u20136.","journal-title":"Am Heart J."},{"issue":"2","key":"192_CR57","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/nrcardio.2010.184","volume":"8","author":"TY Wang","year":"2011","unstructured":"Wang TY, Gutierrez A, Peterson ED. Percutaneous coronary intervention in the elderly. Nat Rev Cardiol. 2011;8(2):79\u201390.","journal-title":"Nat Rev Cardiol."},{"issue":"4","key":"192_CR58","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.ahj.2010.01.010","volume":"159","author":"HL Dauerman","year":"2010","unstructured":"Dauerman HL, Bhatt DL, Gretler DD, et al. Bridging the gap between clinical trials of antiplatelet therapies and applications among elderly patients. Am Heart J. 2010;159(4):508\u201317.","journal-title":"Am Heart J."},{"issue":"17","key":"192_CR59","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1001\/jama.292.17.2096","volume":"292","author":"DL Bhatt","year":"2004","unstructured":"Bhatt DL, Roe MT, Peterson ED, et al. Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. JAMA. 2004;292(17):2096\u2013104.","journal-title":"JAMA."},{"key":"192_CR60","doi-asserted-by":"crossref","first-page":"A1773","DOI":"10.1016\/S0735-1097(15)61773-9","volume":"65","author":"M Cavender","year":"2015","unstructured":"Cavender M, Bhatt DL, Stone G, et al. Cangrelor in elderly patients undergoing PCI: findings from CHAMPION PHOENIX. J Am Coll Cardiol. 2015;65:A1773.","journal-title":"J Am Coll Cardiol."},{"issue":"36","key":"192_CR61","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1093\/eurheartj\/ehu223","volume":"35","author":"A Gutierrez","year":"2014","unstructured":"Gutierrez A, Bhatt DL. Balancing the risks of stent thrombosis and major bleeding during primary percutaneous coronary intervention. Eur Heart J. 2014;35(36):2448\u201351.","journal-title":"Eur Heart J."},{"issue":"3","key":"192_CR62","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.jcin.2014.09.025","volume":"8","author":"HD White","year":"2015","unstructured":"White HD, Bhatt DL, Gibson CM, et al. Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (a clinical trial comparing cangrelor to clopidogrel standard therapy in subjects who require percutaneous coronary intervention [PCI]). JACC Cardiovasc Interv. 2015;8(3):424\u201333.","journal-title":"JACC Cardiovasc Interv."},{"issue":"8","key":"192_CR63","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1161\/CIRCULATIONAHA.106.612812","volume":"114","author":"JW Eikelboom","year":"2006","unstructured":"Eikelboom JW, Mehta SR, Anand SS, et al. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation. 2006;114(8):774\u201382.","journal-title":"Circulation."},{"issue":"9","key":"192_CR64","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.amjcard.2005.06.056","volume":"96","author":"SV Rao","year":"2005","unstructured":"Rao SV, O\u2019Grady K, Pieper KS, et al. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am J Cardiol. 2005;96(9):1200\u20136.","journal-title":"Am J Cardiol."},{"issue":"17","key":"192_CR65","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/j.jacc.2013.08.700","volume":"62","author":"SV Rao","year":"2013","unstructured":"Rao SV, Turi ZG, Wong SC, et al. Radial versus femoral access. J Am Coll Cardiol. 2013;62(17):S11\u201320.","journal-title":"J Am Coll Cardiol."},{"issue":"14","key":"192_CR66","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1093\/eurheartj\/ehv498","volume":"37","author":"JA Gutierrez","year":"2016","unstructured":"Gutierrez JA, Harrington RA, Blankenship JC, et al. The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX. Eur Heart J. 2016;37(14):1122\u201330.","journal-title":"Eur Heart J."},{"issue":"17","key":"192_CR67","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1053\/euhj.2000.2121","volume":"21","author":"JC O\u2019Shea","year":"2000","unstructured":"O\u2019Shea JC, Calif RM. Inter-regional differences in acute coronary syndrome trials. Eur Heart J. 2000;21(17):1397\u20139.","journal-title":"Eur Heart J."},{"issue":"20","key":"192_CR68","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/j.jacc.2008.08.022","volume":"52","author":"PA Poole-Wilson","year":"2008","unstructured":"Poole-Wilson PA. Global differences in the outcome of heart failure: implications for clinical practice. J Am Coll Cardiol. 2008;52(20):1649\u201351.","journal-title":"J Am Coll Cardiol."},{"issue":"6","key":"192_CR69","doi-asserted-by":"crossref","first-page":"e003612","DOI":"10.1161\/CIRCINTERVENTIONS.116.003612","volume":"9","author":"M Vaduganathan","year":"2016","unstructured":"Vaduganathan M, Harrington RA, Stone GW, et al. Variation in patient profiles and outcomes in US and non-US subgroups of the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX trial. Circ Cardiovasc Interv. 2016;9(6):e003612.","journal-title":"Circ Cardiovasc Interv."},{"issue":"5","key":"192_CR70","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1001\/jama.299.5.532","volume":"299","author":"PM Ho","year":"2008","unstructured":"Ho PM, Peterson ED, Wang L, et al. Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. JAMA. 2008;299(5):532\u20139.","journal-title":"JAMA."},{"issue":"3","key":"192_CR71","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1001\/jama.2011.2002","volume":"307","author":"DJ Angiolillo","year":"2012","unstructured":"Angiolillo DJ, Firstenberg MS, Price MJ, et al. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. JAMA. 2012;307(3):265\u201374.","journal-title":"JAMA."},{"issue":"4","key":"192_CR72","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/HPC.0b013e31826c53cd","volume":"11","author":"PH Huang","year":"2012","unstructured":"Huang PH, Croce KJ, Bhatt DL, et al. Recommendations for management of antiplatelet in patients undergoing elective noncardiac surgery after coronary stent implantation. Crit Pathw Cardiol. 2012;11(4):177\u201385.","journal-title":"Crit Pathw Cardiol."},{"issue":"1","key":"192_CR73","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrcardio.2015.113","volume":"13","author":"F Rollini","year":"2016","unstructured":"Rollini F, Franchi F, Angiolillo DJ. Switching P2Y12-receptor inhibitors in patients with coronary artery disease. Nat Rev Cardiol. 2016;13(1):11\u201327.","journal-title":"Nat Rev Cardiol."},{"issue":"1","key":"192_CR74","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/MCA.0000000000000158","volume":"26","author":"DJ Schneider","year":"2015","unstructured":"Schneider DJ, Seecheran N, Raza SS, et al. Pharmacodynamic effects during the transition between cangrelor and prasugrel. Coron Artery Dis. 2015;26(1):42\u20138.","journal-title":"Coron Artery Dis."},{"issue":"4","key":"192_CR75","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.jcin.2013.08.017","volume":"7","author":"DJ Schneider","year":"2014","unstructured":"Schneider DJ, Agarwal Z, Seecheran N, et al. Pharmacodynamic effects during the transition between cangrelor and ticagrelor. JACC Cardiovasc Interv. 2014;7(4):435\u201342.","journal-title":"JACC Cardiovasc Interv."},{"key":"192_CR76","doi-asserted-by":"crossref","unstructured":"Mohammad M, Andell P, Gotberg M, et al. Real-life assessment of cangrelor P2Y12-inhibition in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2016;67(13_S):542.","DOI":"10.1016\/S0735-1097(16)30543-5"},{"issue":"9909","key":"192_CR77","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1016\/S0140-6736(13)61840-1","volume":"382","author":"SR Mehta","year":"2013","unstructured":"Mehta SR. Cangrelor: a new CHAMPION for percutaneous coronary intervention. Lancet. 2013;382(9909):1960\u20132.","journal-title":"Lancet."}],"updated-by":[{"DOI":"10.1007\/s40256-016-0201-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2016,11,11]],"date-time":"2016-11-11T00:00:00Z","timestamp":1478822400000}}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-016-0192-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40256-016-0192-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-016-0192-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,14]],"date-time":"2019-09-14T01:54:00Z","timestamp":1568426040000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40256-016-0192-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,27]]},"references-count":77,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["192"],"URL":"https:\/\/doi.org\/10.1007\/s40256-016-0192-1","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40256-016-0201-4","asserted-by":"object"}]},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,27]]}}}